.svg){kind=small}
03 February 2025
Upcoming Webinar on Tuesday, February 25, 2025 at 15:00 GMT / 16:00 CET / 10:00 EST / 7:00 PST
What's the webinar about?
Biomarkers are essential indicators found in body fluids or tissues that help diagnose, prognose, and monitor diseases, enabling personalized treatments. In neurodegenerative diseases like Alzheimer's, ALS, Parkinson's, and TBI, biomarkers are crucial for early detection and understanding disease progression.
Our webinar will explore key biomarkers such as Neurofilament Light (NfL), Glial Fibrillary Acidic Protein (GFAP), and Tau proteins, highlighting their role in early diagnosis and treatment response.
Discussion points:
- Biomarkers
- Neurodegenerative diseases
- Biomarkers for neurodegenerative diseases and conditions
- Diagnostics of biomarkers
- Alzheimer’s disease, traumatic brain injury (TBI), Parkinson’s disease, ALS, Multiple sclerosis
Key take aways:
- Early Detection: Biomarkers can aid in the early detection of neurodegenerative diseases, enabling timely intervention and better patient outcomes.
- Understanding Disease Mechanisms: Biomarkers help in understanding the progression of neurodegenerative diseases, crucial for developing effective treatments.
- Medix Biochemica's Neurology Portfolio: Medix Biochemica will showcase our high-quality neurology antibodies, antigens, and biospecimens, including new products essential for advancing research and clinical applications.
Our speakers and host for the webinar
Prof. Timo Myöhänen
Professor in Pharmacology, Faculty of Medicine, University of Helsinki
Timo Myöhänen currently holds a professorship in Pharmacology in the Faculty of Medicine at the University of Helsinki. He earned his Ph.D. in Pharmacology in 2008 from the University of Kuopio and completed postdoctoral research at the University of Antwerp in Belgium and Georgetown University in Washington, DC, USA. Since then, he has dedicated much of his career to the University of Helsinki. Throughout his career, Professor Myöhänen’s research has focused on the central nervous system (CNS), particularly neurodegenerative diseases such as Parkinson's and Alzheimer's. For nearly 15 years, his team has worked with models of neurodegenerative diseases, investigating the mechanisms that lead to neuronal death. Their primary research area has been the study of accumulating and aggregating proteins, such as alpha-synuclein and Tau. They have closely collaborated with medicinal chemistry to develop novel compounds aimed at combating neurodegeneration.
Dr. Maria Voutilainen
Global Product Manager, Medix Biochemica
Dr. Maria Voutilainen is the Global Product Manager at Medix Biochemica, where she oversees the Neurology, Hormones, Drugs of Abuse, Veterinary, and Therapeutic Drug Monitoring portfolios. In her current position, she is responsible for the strategic planning, development, and commercialization of these product lines, ensuring they meet the highest standards of quality and efficacy. Maria has extensive experience in the private bioscience sector. She has worked with laboratory instruments, consumables, and in vitro diagnostic (IVD) assays across various stages of the product life cycle, from initial research and development to market launch and post-market support. Maria holds a PhD in Genetics from the University of Helsinki. She is dedicated to science communication and promoting partnerships and dialogue between the private sector and academic institutions.
Anthony Austin
Global Marketing Manager, Medix Biochemica
Anthony is the Global Marketing Manager for Medix Biochemica, starting in 2022. He enters this role after 15 years holding various science focused responsibilities in R&D, Manufacturing,Analytical and Product Management. Prior to Medix Biochemica, he worked in academic labs studying bone metabolism and genetic diseases affecting white blood cells and their ability to fight infections.
